IFNA1 and neoplasm: Concordant with these data, gene set enrichment analysis of tumours treated with either RMC-4550 or RMC-4998 revealed activation of IFN responses (Supplementary Fig. 6f, g), while doublet targeted therapy treated tumours showed enrichment of IFN and inflammatory-related pathways compared to either monotherapy (Fig. 6e).